Shantanu Narayen - Pfizer Lead Independent Director
PFE Stock | USD 27.78 0.19 0.69% |
Director
Mr. Shantanu Narayen is an Independent Director of Pfizer Inc., since September 27, 2013. Mr. Narayen is President and Chief Executive Officer and Director of Adobe Systems Incorporated, a producer of creative and digital marketing software. Prior to his appointment as CEO in December 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development. Director of Dell Inc. from 2009 until October 2013 and Director of Metavante Technologies Inc. from 2007 until 2009. President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world since 2019.
Age | 57 |
Tenure | 5 years |
Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to 0.02. In addition to that, Return On Assets is expected to decline to 0.01. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Paul Clark | Agilent Technologies | 72 | |
Kurt Graves | Seres Therapeutics | 50 | |
Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
Willard Dere | Seres Therapeutics | 64 | |
Robert Herbold | Agilent Technologies | 74 | |
Scott Morenstein | Madrigal Pharmaceuticals | 38 | |
Stephen Connelly | Equillium | 42 | |
Dennis Ausiello | Seres Therapeutics | 72 | |
David Berry | Seres Therapeutics | 37 | |
Renato Esposito | 23Andme Holding Co | N/A | |
Charles McDermott | Equillium | 45 | |
George Scangos | Agilent Technologies | 72 | |
Roy Blom | 23Andme Holding Co | 65 | |
Heidi Kunz | Agilent Technologies | 66 | |
Marc Lavine | Equillium | N/A | |
Dow Wilson | Agilent Technologies | 61 | |
Tadataka Yamada | Agilent Technologies | 74 | |
Heidi Fields | Agilent Technologies | 60 | |
Staffan Gavel | 23Andme Holding Co | 67 | |
Hans Bishop | Agilent Technologies | 56 | |
Giuseppe Lettieri | 23Andme Holding Co | 33 |
Management Performance
Return On Equity | 0.0235 | ||||
Return On Asset | 0.0155 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Shantanu Narayen, Lead Independent Director | ||
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
Susan DesmondHellmann, Independent Director | ||
Stephen Sanger, Independent Director | ||
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
Geno Germano, Group President of Global Innovative Pharma Bus. | ||
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
Mikael MD, Chief Development | ||
Payal Becher, Chief VP | ||
James Quincey, Independent Director | ||
Charles Hill, Executive Vice President - Worldwide Human Resources | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
James Smith, Independent Director | ||
Christopher CFA, VP Officer | ||
Dennis Ausiello, Independent Director | ||
Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Francesca DeMartino, Chief Officer | ||
Frances Fergusson, Independent Director | ||
Gordon Loh, Senior Vice President Corporate Audit | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
DVM DVM, Chairman CEO | ||
William Gray, Independent Director | ||
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Susan Hockfield, Independent Director | ||
Freda LewisHall, Executive Vice President Chief Medical Officer | ||
Albert DVM, Chairman CEO | ||
Dan Littman, Independent Director | ||
Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
James Kilts, Independent Director | ||
Don Cornwell, Independent Director | ||
Andreas Panayiotou, Global Officer | ||
Joseph Echevarria, Independent Director | ||
Scott Gottlieb, Independent Director | ||
Ronald Blaylock, Independent Director | ||
Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0235 | ||||
Return On Asset | 0.0155 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | (0.50) % | ||||
Current Valuation | 214.38 B | ||||
Shares Outstanding | 5.66 B | ||||
Shares Owned By Insiders | 0.04 % | ||||
Shares Owned By Institutions | 69.96 % | ||||
Number Of Shares Shorted | 66.12 M | ||||
Price To Earning | 9.48 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.